L’Hopital Alexandra Lepeve — Clinical Trial Site

19 Registered trials

11 Currently recruiting

Organisation

L’Hopital Alexandra Lepeve

Location

Dunkirk Cedex 1, France

Identifier

ORG-100050350

Address

130 Avenue Louis Herbeaux, Cs 76367, 59385, France

Departments

Cellule Recherche Clinique
Hématologie
Hematology
Hematology Department
Neurology
Service d'Oncologie
Service d’Hépato Gastro-entérologie
Service Hématologie

Clinical trials at this site (19)

Search interface

MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending

2024-513889-19-00 Multiple Myeloma 5
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APP… Pending

2024-516570-30-00 Relapsed/refractory T-cell Acute Lymphoblastic Leukemia 4
A study to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in participants aged 18 years and o… Pending

2025-523117-28-00 Relapsed or Refractory Multiple Myeloma 4
PROlonged Corticosteroid treatment or N-ACetylcysteine for severe alcoholic hepatitis (PROCORNAC) Recruiting

2025-522109-39-00 Alcoholic hepatitis 5 2026-05-22
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum… Recruiting

2025-520897-21-00 Multiple Myeloma 10 2026-02-25
GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran… Recruiting

2024-511437-35-00 Patients aged 18-65 years old with newly diagnosed prev 10 2026-01-05
A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf… Recruiting

2024-516418-39-00 Multiple Myeloma 5 2025-07-09
A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting

2024-515566-13-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2025-03-19
Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit… Recruiting

2024-510981-18-00 Multiple Myeloma Multiple myeloma (MM) is a B cell mali 5 2024-12-12
Multicenter randomized, double-blind, placebo controlled trial evaluating the effect of a 30-week caffeine treatment on cognition in early-t… Recruiting

2024-514099-41-00 Alzheimer's disease 5 2024-10-31
A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma - I… Recruiting

2024-514101-65-00 Multiple Myeloma 4 2023-12-21
Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting

2022-501710-62-02 Peripheral T-cell lymphoma (PTCL) 6 2023-06-07
IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre… Recruiting

2024-517215-67-00 Newly diagnosed Non-Frail transplant Ineligible Multipl 5 2021-06-11
PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer Recruiting

2024-512173-27-00 Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible f 5 2019-03-21
Phase 3 trial aimed at improving the overall survival of AML in adults aged 18 to 60 by comparing high-dose idarubicin with daunorubicin at … Ended

2024-516873-57-00 Acute myeloid leukemia in adults aged 18 to 60 10 2026-01-13
RITUX-PLUS 2 : A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of rituximab combined with subcutane… Ended

2024-516168-27-00 Adult patients with persistent or chronic immune thromb 5 2022-11-10
KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA… Ended

2024-513252-15-00 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL 4 2021-01-28
A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su… Ended

2024-514088-25-00 Multiple Myeloma 5 2019-10-07
A Phase 2 Study combining BGB-3111 with Obinutuzumab compared with Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma Ended

2023-509975-17-00 Relapsed/Refractory Follicular Lymphoma 4 2018-04-12